Early Sedation with Dexmedetomidine in Critically Ill Patients.

Shehabi, Yahya; Howe, Belinda D; Bellomo, Rinaldo; Arabi, Yaseen M; Bailey, Michael; Bass, Frances E; Bin Kadiman, Suhaini; McArthur, Colin J; Murray, Lynnette; Reade, Michael C; Seppelt, Ian M; Takala, Jukka; Wise, Matt P; Webb, Steven A (2019). Early Sedation with Dexmedetomidine in Critically Ill Patients. The New England journal of medicine, 380(26), pp. 2506-2517. Massachusetts Medical Society 10.1056/NEJMoa1904710

	Text 2019 - Shehabi - NEJM - PMID 31112380.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (324kB) | Request a copy
	Text 2019 - Shehabi_Appendix - NEJM - PMID 31112380.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy

BACKGROUND

Dexmedetomidine produces sedation while maintaining a degree of arousability and may reduce the duration of mechanical ventilation and delirium among patients in the intensive care unit (ICU). The use of dexmedetomidine as the sole or primary sedative agent in patients undergoing mechanical ventilation has not been extensively studied.

METHODS

In an open-label, randomized trial, we enrolled critically ill adults who had been undergoing ventilation for less than 12 hours in the ICU and were expected to continue to receive ventilatory support for longer than the next calendar day to receive dexmedetomidine as the sole or primary sedative or to receive usual care (propofol, midazolam, or other sedatives). The target range of sedation-scores on the Richmond Agitation and Sedation Scale (which is scored from -5 [unresponsive] to +4 [combative]) was -2 to +1 (lightly sedated to restless). The primary outcome was the rate of death from any cause at 90 days.

RESULTS

We enrolled 4000 patients at a median interval of 4.6 hours between eligibility and randomization. In a modified intention-to-treat analysis involving 3904 patients, the primary outcome event occurred in 566 of 1948 (29.1%) in the dexmedetomidine group and in 569 of 1956 (29.1%) in the usual-care group (adjusted risk difference, 0.0 percentage points; 95% confidence interval, -2.9 to 2.8). An ancillary finding was that to achieve the prescribed level of sedation, patients in the dexmedetomidine group received supplemental propofol (64% of patients), midazolam (3%), or both (7%) during the first 2 days after randomization; in the usual-care group, these drugs were administered as primary sedatives in 60%, 12%, and 20% of the patients, respectively. Bradycardia and hypotension were more common in the dexmedetomidine group.

CONCLUSIONS

Among patients undergoing mechanical ventilation in the ICU, those who received early dexmedetomidine for sedation had a rate of death at 90 days similar to that in the usual-care group and required supplemental sedatives to achieve the prescribed level of sedation. More adverse events were reported in the dexmedetomidine group than in the usual-care group. (Funded by the National Health and Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov number, NCT01728558.).

Interest & Impact

Downloads

2 since deposited on 05 Aug 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item